(Rac)-Acolbifene is an estrogen receptor antagonist with both antiestrogenic and estrogenic activities; it exhibits potent inhibitory effects on T-47D breast cancer cell growth (IC50 = 0.110 nM); in vivo, it demonstrates significant antiuterotrophic activity in ovariectomized mice, achieving 63% and 84% inhibition at oral doses of 7.5 nM and 75 nM, respectively.